Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer
Shots:
- Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study
- The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety- tolerability- and anti-tumor activity in separate cohorts of subjects with HER2+ BC- HER2-low BC- and non-breast HER2-expressing solid tumors
- Zanidatamab is in the advanced clinical stage- actively enrolling a study in patients with prior treated HER2 gene-amplified BTC while five active P-II programs are underway. ALX148 is a next-generation CD47 blocker and has the potential to expand the chance for zanidatamab to benefits patients with HER2‑expressing BC
Ref: Zymeworks | Image: Medium
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com